Nitrosamine Analysis

Nitrosamine Analysis
Product Description

In response to nitrosamines present in pharmaceutical products, the European Medical Agency (EMA) and the US Food and Drug Administration (US FDA) have published requirements and limits related to nitrosamine contaminants. Therefore Brightlabs has developed and validated multiple methods to determine low level concentrations of Nitrosamines. These methods can easily be adapted to different drug substances or drug products. For you as a pharmaceutical manufacturer, these methods can help in a proactive approach as part of a risk assessment of your products. Brightlabs has an in-house developed and validated method for the determination of low level Nitrosamines screen using GC-MS/MS. All nitrosamines as listed by the EMA are present in this method, and can be measured in very low levels, even as low as < 1 ppb depending on the product and nitrosamine.

Brightlabs

  • NL
  • 2021
    On CPHI since
  • 2
    Certificates
  • 25 - 49
    Employees
Company types
Contract Service
Specifications

Brightlabs

  • NL
  • 2021
    On CPHI since
  • 2
    Certificates
  • 25 - 49
    Employees
Company types
Contract Service

More Products from Brightlabs (3)

  • Elemental Impurities

    Product Elemental Impurities

    Brightlabs has in-house validated methods for the analysis of elemental impurities in accordance to ICH-Q3D. Brightlabs has a unique approach for ICHQ3D, which guarantees quick turnaround times at reduced cost
  • Herbal Drugs Analysis

    Product Herbal Drugs Analysis

    Since 2018 Brightlabs possesses an opium exemption from the BMC (Bureau for Medicinal Cannabis), for the analysis of cannabis and related products. The combination of this opium exemption, combined with our GMP accreditation, makes Brightlabs an important partner for the analysis of cannabis and related ma...
  • Method Development

    Product Method Development

    We are specialist in the method development of analytical methods for analysis of API, Final Drug Products or low level impurities. Usually followed by full validation in accordance to ICH guidelines.

Brightlabs resources (1)